Can JAK2V617F VAF variations help predict clinical and survival outcomes?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub was pleased to speak to Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, Can JAK2V617F variant allele frequency (VAF) variations help predict clinical and survival outcomes?
Harrison opens by discussing the latest data presented at the 64th ASH Annual Meeting and Exposition from a range of studies on the relationship between JAK2V617F VAF variations and progression-free survival, event-free survival, overall survival, and molecular response. Harrison concludes by outlining the promising developments for molecular monitoring in the field of myeloproliferative neoplasms.

[@vanloosc]

When molecular JAK2V617F response is key in future PV threatment, does that favour the role of peginterferon alfa over hydroxyurea?

[@keithray7928]

Truth is experts don't know that much. They have no answers